Gastrointestinal adverse events with insulin glargine/lixisenatide fixed-ratio combination versus glucagon-like peptide-1 receptor agonists in people with type 2 diabetes mellitus: A network meta-analysis.
Christopher K RaynerChinmay S MaratheVanita R ArodaCraig WhittingtonSteve KantersPatricia GuyotAlka ShaunikMichael HorowitzPublished in: Diabetes, obesity & metabolism (2020)
During the first 12 weeks of treatment, iGlarLixi was generally associated with less nausea and vomiting than single-agent GLP-1 RAs. Enhanced gastrointestinal tolerability with fixed-ratio combinations may favour treatment persistence.